Patents Issued in January 16, 2024
-
Patent number: 11872198Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.Type: GrantFiled: June 9, 2021Date of Patent: January 16, 2024Assignee: Purdue Research FoundationInventors: Kee-Hong Kim, Yuyan Zhu
-
Patent number: 11872199Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.Type: GrantFiled: January 9, 2023Date of Patent: January 16, 2024Assignee: SMARTECH TOPICAL, INC.Inventor: Thomas Hnat
-
Patent number: 11872200Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: March 22, 2021Date of Patent: January 16, 2024Assignee: The Regents of the University of CaliforniaInventors: Daniel L Kaufman, Jide Tian
-
Patent number: 11872201Abstract: There is provided a vegetable-based lipid composition comprising very high levels of DHA, together with at least one other long-chain polyunsaturated fatty acid (typically as fatty acid esters). The composition typically contains low levels of EPA and palmitic acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.Type: GrantFiled: December 20, 2018Date of Patent: January 16, 2024Assignee: Nuseed Nutritional US Inc.Inventor: Stuart Littler
-
Patent number: 11872202Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.Type: GrantFiled: March 15, 2022Date of Patent: January 16, 2024Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Chengyuan Liang, Xiuding Yang, Liang Xin, Juan Xia, Yuqing Zhao, Jie Zhang, Lei Tian, Jingyi Li, Shaojun Zhang, Qianqian Zhao
-
Patent number: 11872203Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: May 24, 2023Date of Patent: January 16, 2024Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11872204Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: May 24, 2023Date of Patent: January 16, 2024Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11872205Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).Type: GrantFiled: January 26, 2023Date of Patent: January 16, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Gerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11872206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: July 1, 2022Date of Patent: January 16, 2024Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11872207Abstract: The present application relates to methods of using compounds of Formulae (I) and (II): for treatment of various cancers. The application further relates to pharmaceutical compositions and uses comprising the compounds of the application.Type: GrantFiled: January 31, 2020Date of Patent: January 16, 2024Assignee: MCMASTER UNIVERSITYInventors: Katarzyna Jerzak, Sukhbinder Dhesy-Thind, Anita Bane, Jessica Cockburn, John Hassell
-
Patent number: 11872208Abstract: The present invention relates to a veterinary or pharmaceutical composition comprising: (i) about 1-65% w/v of a pyrethroid, or a salt thereof, (ii) a macrocyclic lactone, or a salt thereof, (iii) at least one alkalizing agent, (iv) at least one non aqueous solvent, wherein the pH of the composition is comprised between about 6.5 and 8.5, when measured by adding 25% of water to an aliquot of said composition. The invention further relates to the use of such composition for preventing and/or treating parasites infestations.Type: GrantFiled: November 23, 2018Date of Patent: January 16, 2024Assignee: CEVA SANTE ANIMALEInventors: Florence Guimberteau, Sandrine Lacoste, Romain Delcombel, Hamadi Karembe
-
Patent number: 11872209Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.Type: GrantFiled: April 14, 2023Date of Patent: January 16, 2024Assignee: Zydus Lifesciences LimitedInventors: Mukul R. Jain, Deven V. Parmar, Suresh Giri, Binu Philip, Pankaj Patel
-
Patent number: 11872210Abstract: Disclosed herein is a method of administering to a patient in need thereof a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound to treat or prevent a disease or condition influenced by the activity of one or more extracellular thiol isomerases (e.g. protein disulfide isomerase, ERp5, ERp57, ERp72 and thioredoxin). The disease or condition includes arterial thrombosis, venous thrombosis, a thrombotic disease, a cancer, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, and a neurodegenerative disorder.Type: GrantFiled: January 29, 2018Date of Patent: January 16, 2024Assignee: WESTERN NEW ENGLAND UNIVERSITYInventors: Daniel Kennedy, Jonathan Gibbins, Lisa-Marie Holbrook
-
Patent number: 11872211Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.Type: GrantFiled: May 19, 2023Date of Patent: January 16, 2024Assignee: SPRINGWORKS THERAPEUTICS, INC.Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
-
Patent number: 11872212Abstract: The invention provides non-centrosymmetric organic crystals which show exceptional self-healing properties. More particularly, the present invention provides non-centrosymmetric substituted imidazole and Dialkyl 4,4?-methylenebis(azanediyl)dibenzoate Crystals and a process for preparation thereof. These highly crystalline materials, when broken into pieces, can self-propel and re-join in the blink of an eye and repair themselves so precisely that they become indistinguishable from the undisturbed materials.Type: GrantFiled: July 26, 2022Date of Patent: January 16, 2024Assignee: Indian Institute of Science Education and Research (IISER) KolkataInventors: Chilla Malla Reddy, Surojit Bhunia, Rituparno Chowdhury, Ishita Ghosh
-
Patent number: 11872213Abstract: Described herein are formulations including pharmaceutical agents comprising ester and/or lactone ring structures, and methods of using the same. The invention is also directed to a method and ophthalmic pharmaceutical compositions including solution and semisolid dosage forms (i.e. ophthalmic creams, gels, lotions, serums, and/or ointments) of treating a patient with various ocular diseases including presbyopia and dry eyes. The method comprising instructing a patient to apply one strip of the ophthalmic composition to the eyelids that includes pilocarpine or other active pharmaceutical ingredients containing ester and/or lactone ring structures with and without the buffering system.Type: GrantFiled: January 28, 2022Date of Patent: January 16, 2024Assignee: Glaukos CorporationInventors: Xiaojun Michael Liu, James Jane-Guo Shiah, Gabriella Szekely
-
Patent number: 11872214Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: January 16, 2024Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11872215Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.Type: GrantFiled: January 22, 2021Date of Patent: January 16, 2024Assignee: University of Georgia Research Foundation, Inc.Inventor: Geert-Jan Boons
-
Patent number: 11872216Abstract: The present invention relates to a pharmaceutical formulation in powder form comprising amoxicillin, cineole and a pharmaceutically acceptable oil. The present formulation may also comprise clavulanic acid. It is intended for oral administration, preferably after suspension in an aqueous solvent. The present invention also relates to a combination of cineole and amoxicillin for use in the treatment of an infectious pathology, preferably a bacterial infection, in an individual. The present combination may also comprise a ?-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to combat infections caused by bacteria that are resistant to antibiotics, preferably to antibiotics of the ?-lactamine family.Type: GrantFiled: June 2, 2017Date of Patent: January 16, 2024Assignee: ADVANCED SCIENTIFIC DEVELOPMENTSInventors: Adnane Remmal, Ahmed Amine Akhmouch
-
Patent number: 11872217Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.Type: GrantFiled: July 9, 2020Date of Patent: January 16, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11872218Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.Type: GrantFiled: December 23, 2021Date of Patent: January 16, 2024Assignee: BAUSCH HEALTH IRELAND LIMITEDInventors: Gareth Winckle, Gregory T. Fieldson
-
Patent number: 11872219Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.Type: GrantFiled: May 24, 2021Date of Patent: January 16, 2024Assignee: Centrexion Therapeutics CorporationInventors: James N. Campbell, Barton Harley Manning
-
Patent number: 11872220Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.Type: GrantFiled: August 8, 2022Date of Patent: January 16, 2024Assignee: Janssen Pharmaceutica NVInventors: Eric Frederik Eldering, Karoline Kielbassa, Ulrike Philippar, Andrew Steele, Marco Vincent Haselager, A. P. Kater
-
Patent number: 11872221Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.Type: GrantFiled: January 29, 2021Date of Patent: January 16, 2024Assignee: HUA Medicine (Shanghai) Ltd.Inventors: Li Chen, Shuang Ren, Jiayi Zhang
-
Patent number: 11872222Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.Type: GrantFiled: May 28, 2021Date of Patent: January 16, 2024Assignee: NeRRe Therapeutics LimitedInventors: Mike Trower, Stephen Pawsey, Mary Kerr
-
Patent number: 11872223Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.Type: GrantFiled: March 16, 2022Date of Patent: January 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng Li
-
Patent number: 11872224Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.Type: GrantFiled: December 29, 2021Date of Patent: January 16, 2024Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co. (Beijing), Ltd.Inventors: Chi-Feng Yen, Fang-Wei Tien
-
Patent number: 11872225Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.Type: GrantFiled: January 27, 2022Date of Patent: January 16, 2024Assignee: Agios Pharmaceuticals, Inc.Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
-
Patent number: 11872226Abstract: The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.Type: GrantFiled: February 7, 2020Date of Patent: January 16, 2024Assignee: MEDIBIOFARMA, S.L.Inventors: Julio Castro Palomino Laria, Juan Camacho Gómez, Rodolfo Rodríguez Iglesias, Irene Velilla Martínez
-
Patent number: 11872227Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.Type: GrantFiled: May 10, 2022Date of Patent: January 16, 2024Assignee: ACETYLON PHARMACEUTICALS, INC.Inventors: Brian North, Steven Quayle
-
Patent number: 11872228Abstract: The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF?.Type: GrantFiled: December 21, 2021Date of Patent: January 16, 2024Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: In Kyu Lee, Eun Jung Choi, Chang Hyun Jeon, Tae-Hwan Kwon, Dong Ho Park
-
Patent number: 11872229Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.Type: GrantFiled: October 28, 2020Date of Patent: January 16, 2024Assignee: Principia Biopharma Inc.Inventors: Abu J. Ferdous, Mohammad R. Masjedizadeh, Wu Lin
-
Patent number: 11872230Abstract: The present invention relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.Type: GrantFiled: May 16, 2022Date of Patent: January 16, 2024Assignee: Agency for Science, Technology and ResearchInventors: Zhenxun Wang, Wai Leong Tam, Lian Yee Yip, Ying Swan Ho, Zhengwei Wu, Bing Lim
-
Patent number: 11872231Abstract: The disclosure provides a composition configured for oral use, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.Type: GrantFiled: December 9, 2019Date of Patent: January 16, 2024Assignee: Nicoventures Trading LimitedInventors: Christopher Keller, Ronald K. Hutchens, Thomas H. Poole, Nicolas von Cosmos, Anthony Richard Gerardi, Chris J. Grimes, Steven Lee Alderman, Darrell Eugene Holton, Jr.
-
Patent number: 11872232Abstract: Provided herein include caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. Also provided are methods for the production of caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. In some embodiments, disclosed compositions may provide consumers with increased alertness and wakefulness, while preventing side effects commonly associated with caffeinated drinks.Type: GrantFiled: April 12, 2023Date of Patent: January 16, 2024Assignee: RAREBIRD, INC.Inventors: Jeffrey Dietrich, Maddison Kylie Gurrola, Amanda Jacklyn Grace Sinrod, Edwin Yparraguirre Palang
-
Patent number: 11872233Abstract: Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.Type: GrantFiled: June 5, 2019Date of Patent: January 16, 2024Assignee: IC-MedTech Corp.Inventors: Sueli de Oliveira Silva Lautenschlager, Vania Cristina Desoti, Celso Vataru Nakamura, Valdecir Farias Ximenes
-
Patent number: 11872234Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.Type: GrantFiled: April 10, 2023Date of Patent: January 16, 2024Assignee: Par Pharmaceutical, Inc.Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
-
Patent number: 11872235Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one. Pharmaceutical compositions and the dosage forms of the bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters can be used to treat any condition associated with testosterone deficiency, including complete absence of endogenous testosterone in male or female subjects.Type: GrantFiled: March 15, 2022Date of Patent: January 16, 2024Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
-
Patent number: 11872236Abstract: Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human ?-A-crystallin. Compositions containing certain compounds are believed to be also effective in the treatment of transthyretin (TTR)-associated amyloidosis and Parkinson's disease.Type: GrantFiled: April 5, 2019Date of Patent: January 16, 2024Assignee: CALASIA PHARMACEUTICALS, INC.Inventors: Surya Kanta De, Sridhar G. Prasad, Marshall Clarke Peterman, Bernard Collins
-
Patent number: 11872237Abstract: The present invention relates to a pharmaceutical composition comprising a sulfonamide as an inhibitor of Bcl-2/Bcl-xL, especially compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoromethyl sulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester or a pharmaceutically acceptable salt thereof and suitable excipients, preferably a pharmaceutical composition in the form of a lyophilized powder. The invention also relates to a method for preparing the pharmaceutical composition.Type: GrantFiled: December 12, 2019Date of Patent: January 16, 2024Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Ming Guo, Yanqiong Lin, Zhenzhong Shao, Pengfei Cao
-
Patent number: 11872238Abstract: Use of a sialyllactose, or a nutritional composition comprising a sialyllactose, to enhance attention and/or to decrease impulsivity in a subject.Type: GrantFiled: May 22, 2018Date of Patent: January 16, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Jonas Hauser, Simone Macri
-
Patent number: 11872239Abstract: The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.Type: GrantFiled: April 20, 2018Date of Patent: January 16, 2024Assignee: Synthena AGInventors: Wolfgang Andreas Renner, Branislav Dugovic, Reto Bertolini
-
Patent number: 11872240Abstract: The present invention relates to antimicrobial formulations comprising Vitamin D as carrier loaded with an antibiotic. More specifically, the present invention relates to antimicrobial compositions comprising vitamin D as carrier loaded with an antibiotic for controlling infections and managing potentially infected wounds or infected wounds or treating infected implants used in orthopaedic surgery and various other conditions leading to healing of the wounds and avoidance of development of antibacterial resistance and avoiding complications related to the use of prolonged antibiotics by systemic route.Type: GrantFiled: August 6, 2019Date of Patent: January 16, 2024Inventors: Chander Shekhar, Khalid Khan, Shruti Kaushik
-
Patent number: 11872241Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.Type: GrantFiled: November 26, 2019Date of Patent: January 16, 2024Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
-
Patent number: 11872242Abstract: A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; and administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc.Type: GrantFiled: June 17, 2021Date of Patent: January 16, 2024Inventor: Sabine Hazan
-
Patent number: 11872243Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: GrantFiled: January 6, 2020Date of Patent: January 16, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
-
Patent number: 11872244Abstract: A method of treatment includes agitating a thixotropic oxidized cellulose solution; administering the agitated thixotropic oxidized cellulose solution to a target tissue site; and allowing the agitated thixotropic oxidized cellulose solution to gel at the target tissue site.Type: GrantFiled: July 31, 2019Date of Patent: January 16, 2024Assignee: Covidien LPInventors: Rachit Ohri, Phillip D. Blaskovich, Min-Shyan Sheu, Petra Brockfeld
-
Patent number: 11872245Abstract: According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).Type: GrantFiled: December 21, 2021Date of Patent: January 16, 2024Assignee: TRIMPH IP PTY LIMITEDInventors: Ali Fathi, Fariba Dehghani
-
Patent number: 11872246Abstract: A nutritional supplement provides Vitamin E; Sophora flavescens extract; zinc sulfate; and a remainder of at least one of the following ingredients: grape seed extract; boswellia extract; micronized Resveratrol; Vitamin B6; black pepper; magnolia powder; poplar powder; willow bark powder; methyl sulfano methane; chia; Vitamin C; Pine powder; Curcumin; Oregano; Ginger; Orange peel; and Meadow sweet. The supplement can be used to reduce joint inflammation, reduce stiffness, reduce lameness, improve flexion, and improve amount of movement and mobility by supporting joint health.Type: GrantFiled: February 14, 2023Date of Patent: January 16, 2024Inventor: Frank Kelly Reilly, III
-
Patent number: 11872247Abstract: The present invention relates to the use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds. The present invention further relates to a method for treating wounds, comprising rinsing the wound with a wound solution and treating the wound with cold atmospheric plasma.Type: GrantFiled: January 24, 2019Date of Patent: January 16, 2024Assignee: Westfaelische Wilhelms-Universitaet MuensterInventor: Heinrich Rotering